MiMedx Group is trading 10.9% down at $3.77 in after-hours trading after reporting a 35% year-over-year decline in net sales and announcing a $350 million deal to acquire Sanara MedTech.
- The revenue slump was driven by a 61% drop in wound-care sales following Medicare reimbursement changes, which overshadowed a 15% increase in surgical growth.
- Investors are focused on the integration risks and costs of the Sanara acquisition, despite management reaffirming 2026 revenue targets and near-breakeven EBITDA guidance.